KLRS
HEALTHCAREKalaris Therapeutics Inc
$5.06-0.24 (-4.53%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving KLRS Today?
No stock-specific AI insight has been generated for KLRS yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.14$11.88
$5.06
Fundamentals
Market Cap$116M
P/E Ratio—
EPS$-2.85
Dividend Yield—
Dividend / Share—
ROE-3.1%
Profit Margin—
Debt / Equity—
Trading
Volume106K
Avg Volume (10D)—
Shares Outstanding23.0M
KLRS News
18 articles- Kalaris Reports Full Year 2025 Financial Results and Provides Business UpdatesYahoo Finance·Mar 17, 2026
- Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual MeetingYahoo Finance·Jan 28, 2026
- Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private PlacementYahoo Finance·Dec 17, 2025
- Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMDYahoo Finance·Dec 17, 2025
- We Think Kalaris Therapeutics (NASDAQ:KLRS) Needs To Drive Business Growth CarefullyYahoo Finance·Nov 27, 2025
- Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity ConferenceYahoo Finance·Nov 24, 2025
- Kalaris Reports Third Quarter 2025 Financial Results and Provides Business UpdatesYahoo Finance·Nov 12, 2025
- Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial OfficerYahoo Finance·Nov 3, 2025
- Kalaris to Present at Stifel 2025 Annual Healthcare ConferenceYahoo Finance·Oct 30, 2025
- Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) biggest owners are private equity firms who got richer after stock soared 24% last weekYahoo Finance·Sep 28, 2025
- UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular DegenerationYahoo Finance·Sep 15, 2025
- Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular DegenerationYahoo Finance·Sep 15, 2025
- Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Sep 1, 2025
- Kalaris Reports Second Quarter 2025 Financial Results and Provides Business UpdatesYahoo Finance·Aug 13, 2025
- We're Hopeful That Kalaris Therapeutics (NASDAQ:KLRS) Will Use Its Cash WiselyYahoo Finance·Jun 20, 2025
- Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity ConferenceYahoo Finance·Jun 2, 2025
- Kalaris to Participate at Stifel Ophthalmology ForumYahoo Finance·May 23, 2025
- Kalaris Reports First Quarter 2025 Financial Results and Provides Business HighlightsYahoo Finance·May 14, 2025
All 18 articles loaded
Price Data
Open$5.51
Previous Close$5.30
Day High$5.62
Day Low$5.20
52 Week High$11.88
52 Week Low$2.14
52-Week Range
$2.14$11.88
$5.06
Fundamentals
Market Cap$116M
P/E Ratio—
EPS$-2.85
Dividend Yield—
Dividend / Share—
ROE-3.1%
Profit Margin—
Debt / Equity—
Trading
Volume106K
Avg Volume (10D)—
Shares Outstanding23.0M
About Kalaris Therapeutics Inc
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. The company is headquartered in Palo Alto, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—